Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial-Reference-Cited by-同舟云学术

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

Published:2017-07 Issue:4 Volume:18 Page:e289-e296
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Park Cheol-Kyu^ORCID,Oh In-Jae^ORCID,Kim Kyu-Sik,Choi Yoo-Duk,Jang Tae-Won,Kim Youn-Seup,Lee Kwan-Ho,Shin Kyeong-Cheol,Jung Chi Young^ORCID,Yang Sei-Hoon,Ryu Jeong-Seon,Jang Seung-Hun,Yoo Seung-Soo,Yong Suk-Joong,Lee Kye Young^ORCID,In Kwang-Ho,Lee Min-Ki,Kim Young-Chul^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

2. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial;Yang;J Thorac Oncol,2010

3. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

4. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer;Paz-Ares;J Clin Oncol,2013

5. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: a cross-trial comparison of two phase III trials;Scagliotti;Lung Cancer,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review;Frontiers in Pharmacology;2023-06-13

2. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis;Lung Cancer;2022-08

3. FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer;The International Journal of Biological Markers;2022-07-06

4. Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer;Frontiers in Surgery;2022-05-16

5. Misleading Reporting (Spin) in Noninferiority Randomized Clinical Trials in Oncology With Statistically Not Significant Results;JAMA Network Open;2021-12-07